Dear visitors and patients,

welcome to the homepage of the Section for Translational Neurodegeneration "Albrecht Kossel" of the Department of Neurology at the University Medical Center in Rostock.

The section consists of several research groups, which deal with basic scientific questions about the development and pathophysiology of neurodegenerative diseases (e.g. amyotrophic lateral sclerosis, Niemann-Pick type C, Wilson's disease), as well as with clinical questions and modern concept of patient centered care and the transfer of new findings from basic science into clinical practice (e.g. for improved diagnostics or the therapy of neurodegenerative diseases) and vice versa.

We combine long standing traditions of neuroscientific research at the Rostock University Medical Center by working on neurodegenerative diseases with up-to-date human stem cell-based cell systems. This mainly includes the use of patient-specific models and the development of individualized therapeutical strategies for neurodegenerative diseases.

Thank you for your interest in our work!


Yours sincerely,

Prof. Dr. Dr. Andreas Hermann, Section head



International Parkinson and Movement Disorder Society

Special Series: Approach to patients with genetic choreas (Prof. Emilia Gatto & Dr. Kevin Peikert)


With your donation you are actively helping and giving people with neurodegenerative diseases courage for the future - a future in which hopefully one or the other neurodegenerative disease will one day be curable.

Donation account

Book release

We are a supporting partner of the European Rare Disease Network (ERN-RND)

European reference network (ERN):

Open positions

Mehr Infos

Book release

News from clinic and basic research

Article on the pathophysiology of ALS

New article published on the impact of defective DNA repair on the formation of FUS protein aggregates in the cytoplasm of motor neurons.

Mehr Infos

Edaravone therapy in ALS

Edaravone, a drug previously approved for ALS in the US and Japan, has not yet been approved in the EU.

Mehr Infos

RELYVRIO approved by ALS in USA

On September 29, 2022 the US Food and Drug Administration (FDA) approved AMX0035 (sodium phenylbutyrate and ursodoxiltaurine) for the treatment of adults with amyotrophic lateral sclerosis (ALS) under the brand name RELYVRIO. Approval is currently being applied for in the European Union (EU), and a final statement from the European Medicines Agency (EMA) is expected in the first half of 2023.

Unfortunately, the preparation will not be available in Europe until then. The only access to AMX0035 in Europe is participation in the PHOENIX drug study, in which our special consultation hours also take part. For more information on the study, including eligibility criteria and participating sites, visit

Mehr Infos

Rasagilin at ALS

In a phase II study, rasagiline was used in ALS patients. Although it probably will not have an effect on the survival of all ALS patients, it will probably have a positive effect in rapidly progressing ALS.


Mehr Infos

New drug approved for SMA

Gene therapy Spinraza® approved in the EU for the treatment of spinal muscular atrophy

Mehr Infos